Complement Ther Med:小青龙汤治疗常年性变应性鼻炎的效果和安全性多中心研究

2019-08-07 AlexYang MedSci原创

小青龙汤(SCRT)是一种混合的中草药,常用于治疗过敏性鼻炎、支气管炎、过敏性哮喘和普通感冒。最近,有研究人员评估了SCRT在治疗过敏性鼻炎中的疗效和安全性情况。研究人员进行的是一个双盲、随机、安慰剂对照、平衡组和多中心的研究。主要结果为总鼻症状评分的变化,次级结果包括了鼻炎生活治疗调查问卷得分变化,总血清免疫球蛋白E(lgE)变化和细胞因子水平以及鼻内镜指数变化。研究发现,在PAR患者中4周的S

小青龙汤(SCRT)是一种混合的中草药,常用于治疗过敏性鼻炎、支气管炎、过敏性哮喘和普通感冒。最近,有研究人员评估了SCRT在治疗过敏性鼻炎中的疗效和安全性情况。

研究人员进行的是一个双盲、随机、安慰剂对照、平衡组和多中心的研究。主要结果为总鼻症状评分的变化,次级结果包括了鼻炎生活治疗调查问卷得分变化,总血清免疫球蛋白E(lgE)变化和细胞因子水平以及鼻内镜指数变化。研究发现,在PAR患者中4周的SCRT药物治疗后,患者的鼻症状和生活质量评分均得到了改善,但是这些效果在药物治疗结束第8周时消失。血清lgE、嗜酸性粒细胞数和细胞因子在药物治疗后没有改变。鼻内镜指数也没有明显的差异。另外,研究人员也没有发现严重的副作用事件和安全性评估变化。

最后,研究人员指出了,SCRT是治疗慢性、常年性和中度到重度AR患者的有效和安全的药物。然而,更长时间的药物使用以及更大群体的研究是需要的,从而鉴定上述结果和阐明药物作用机制。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2117614, encodeId=922d211e6148f, content=<a href='/topic/show?id=616f4e1889c' target=_blank style='color:#2F92EE;'>#小青龙汤#</a>治疗常年性<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47188, encryptionId=616f4e1889c, topicName=小青龙汤), TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 01:46:03 CST 2023, time=2023-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1909503, encodeId=1edf1909503e8, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Dec 14 00:31:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903992, encodeId=fcd9190399265, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jan 17 02:31:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783551, encodeId=16ea1e83551ac, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Jun 06 03:31:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773288, encodeId=ac4b1e7328892, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Wed Jun 17 15:31:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323318, encodeId=0bb6132331834, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609918, encodeId=b9301609918a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370933, encodeId=5e0a3e09338c, content=所以,并没有客观证据显示治疗有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Thu Aug 08 07:00:30 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046886, encodeId=982b10468860d, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Aug 07 16:31:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370896, encodeId=88b93e0896e3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Aug 07 14:02:31 CST 2019, time=2019-08-07, status=1, ipAttribution=)]
    2023-03-05 lifestar 来自上海
  2. [GetPortalCommentsPageByObjectIdResponse(id=2117614, encodeId=922d211e6148f, content=<a href='/topic/show?id=616f4e1889c' target=_blank style='color:#2F92EE;'>#小青龙汤#</a>治疗常年性<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47188, encryptionId=616f4e1889c, topicName=小青龙汤), TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 01:46:03 CST 2023, time=2023-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1909503, encodeId=1edf1909503e8, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Dec 14 00:31:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903992, encodeId=fcd9190399265, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jan 17 02:31:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783551, encodeId=16ea1e83551ac, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Jun 06 03:31:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773288, encodeId=ac4b1e7328892, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Wed Jun 17 15:31:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323318, encodeId=0bb6132331834, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609918, encodeId=b9301609918a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370933, encodeId=5e0a3e09338c, content=所以,并没有客观证据显示治疗有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Thu Aug 08 07:00:30 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046886, encodeId=982b10468860d, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Aug 07 16:31:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370896, encodeId=88b93e0896e3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Aug 07 14:02:31 CST 2019, time=2019-08-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2117614, encodeId=922d211e6148f, content=<a href='/topic/show?id=616f4e1889c' target=_blank style='color:#2F92EE;'>#小青龙汤#</a>治疗常年性<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47188, encryptionId=616f4e1889c, topicName=小青龙汤), TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 01:46:03 CST 2023, time=2023-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1909503, encodeId=1edf1909503e8, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Dec 14 00:31:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903992, encodeId=fcd9190399265, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jan 17 02:31:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783551, encodeId=16ea1e83551ac, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Jun 06 03:31:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773288, encodeId=ac4b1e7328892, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Wed Jun 17 15:31:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323318, encodeId=0bb6132331834, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609918, encodeId=b9301609918a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370933, encodeId=5e0a3e09338c, content=所以,并没有客观证据显示治疗有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Thu Aug 08 07:00:30 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046886, encodeId=982b10468860d, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Aug 07 16:31:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370896, encodeId=88b93e0896e3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Aug 07 14:02:31 CST 2019, time=2019-08-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2117614, encodeId=922d211e6148f, content=<a href='/topic/show?id=616f4e1889c' target=_blank style='color:#2F92EE;'>#小青龙汤#</a>治疗常年性<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47188, encryptionId=616f4e1889c, topicName=小青龙汤), TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 01:46:03 CST 2023, time=2023-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1909503, encodeId=1edf1909503e8, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Dec 14 00:31:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903992, encodeId=fcd9190399265, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jan 17 02:31:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783551, encodeId=16ea1e83551ac, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Jun 06 03:31:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773288, encodeId=ac4b1e7328892, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Wed Jun 17 15:31:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323318, encodeId=0bb6132331834, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609918, encodeId=b9301609918a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370933, encodeId=5e0a3e09338c, content=所以,并没有客观证据显示治疗有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Thu Aug 08 07:00:30 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046886, encodeId=982b10468860d, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Aug 07 16:31:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370896, encodeId=88b93e0896e3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Aug 07 14:02:31 CST 2019, time=2019-08-07, status=1, ipAttribution=)]
    2020-06-06 zsyan
  5. [GetPortalCommentsPageByObjectIdResponse(id=2117614, encodeId=922d211e6148f, content=<a href='/topic/show?id=616f4e1889c' target=_blank style='color:#2F92EE;'>#小青龙汤#</a>治疗常年性<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47188, encryptionId=616f4e1889c, topicName=小青龙汤), TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 01:46:03 CST 2023, time=2023-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1909503, encodeId=1edf1909503e8, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Dec 14 00:31:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903992, encodeId=fcd9190399265, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jan 17 02:31:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783551, encodeId=16ea1e83551ac, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Jun 06 03:31:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773288, encodeId=ac4b1e7328892, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Wed Jun 17 15:31:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323318, encodeId=0bb6132331834, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609918, encodeId=b9301609918a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370933, encodeId=5e0a3e09338c, content=所以,并没有客观证据显示治疗有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Thu Aug 08 07:00:30 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046886, encodeId=982b10468860d, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Aug 07 16:31:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370896, encodeId=88b93e0896e3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Aug 07 14:02:31 CST 2019, time=2019-08-07, status=1, ipAttribution=)]
    2020-06-17 xuyong536
  6. [GetPortalCommentsPageByObjectIdResponse(id=2117614, encodeId=922d211e6148f, content=<a href='/topic/show?id=616f4e1889c' target=_blank style='color:#2F92EE;'>#小青龙汤#</a>治疗常年性<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47188, encryptionId=616f4e1889c, topicName=小青龙汤), TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 01:46:03 CST 2023, time=2023-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1909503, encodeId=1edf1909503e8, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Dec 14 00:31:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903992, encodeId=fcd9190399265, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jan 17 02:31:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783551, encodeId=16ea1e83551ac, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Jun 06 03:31:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773288, encodeId=ac4b1e7328892, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Wed Jun 17 15:31:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323318, encodeId=0bb6132331834, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609918, encodeId=b9301609918a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370933, encodeId=5e0a3e09338c, content=所以,并没有客观证据显示治疗有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Thu Aug 08 07:00:30 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046886, encodeId=982b10468860d, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Aug 07 16:31:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370896, encodeId=88b93e0896e3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Aug 07 14:02:31 CST 2019, time=2019-08-07, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2117614, encodeId=922d211e6148f, content=<a href='/topic/show?id=616f4e1889c' target=_blank style='color:#2F92EE;'>#小青龙汤#</a>治疗常年性<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47188, encryptionId=616f4e1889c, topicName=小青龙汤), TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 01:46:03 CST 2023, time=2023-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1909503, encodeId=1edf1909503e8, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Dec 14 00:31:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903992, encodeId=fcd9190399265, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jan 17 02:31:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783551, encodeId=16ea1e83551ac, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Jun 06 03:31:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773288, encodeId=ac4b1e7328892, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Wed Jun 17 15:31:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323318, encodeId=0bb6132331834, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609918, encodeId=b9301609918a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370933, encodeId=5e0a3e09338c, content=所以,并没有客观证据显示治疗有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Thu Aug 08 07:00:30 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046886, encodeId=982b10468860d, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Aug 07 16:31:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370896, encodeId=88b93e0896e3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Aug 07 14:02:31 CST 2019, time=2019-08-07, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2117614, encodeId=922d211e6148f, content=<a href='/topic/show?id=616f4e1889c' target=_blank style='color:#2F92EE;'>#小青龙汤#</a>治疗常年性<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47188, encryptionId=616f4e1889c, topicName=小青龙汤), TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 01:46:03 CST 2023, time=2023-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1909503, encodeId=1edf1909503e8, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Dec 14 00:31:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903992, encodeId=fcd9190399265, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jan 17 02:31:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783551, encodeId=16ea1e83551ac, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Jun 06 03:31:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773288, encodeId=ac4b1e7328892, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Wed Jun 17 15:31:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323318, encodeId=0bb6132331834, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609918, encodeId=b9301609918a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370933, encodeId=5e0a3e09338c, content=所以,并没有客观证据显示治疗有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Thu Aug 08 07:00:30 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046886, encodeId=982b10468860d, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Aug 07 16:31:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370896, encodeId=88b93e0896e3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Aug 07 14:02:31 CST 2019, time=2019-08-07, status=1, ipAttribution=)]
    2019-08-08 Midas

    所以,并没有客观证据显示治疗有效。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2117614, encodeId=922d211e6148f, content=<a href='/topic/show?id=616f4e1889c' target=_blank style='color:#2F92EE;'>#小青龙汤#</a>治疗常年性<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47188, encryptionId=616f4e1889c, topicName=小青龙汤), TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 01:46:03 CST 2023, time=2023-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1909503, encodeId=1edf1909503e8, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Dec 14 00:31:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903992, encodeId=fcd9190399265, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jan 17 02:31:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783551, encodeId=16ea1e83551ac, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Jun 06 03:31:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773288, encodeId=ac4b1e7328892, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Wed Jun 17 15:31:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323318, encodeId=0bb6132331834, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609918, encodeId=b9301609918a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370933, encodeId=5e0a3e09338c, content=所以,并没有客观证据显示治疗有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Thu Aug 08 07:00:30 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046886, encodeId=982b10468860d, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Aug 07 16:31:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370896, encodeId=88b93e0896e3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Aug 07 14:02:31 CST 2019, time=2019-08-07, status=1, ipAttribution=)]
    2019-08-07 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2117614, encodeId=922d211e6148f, content=<a href='/topic/show?id=616f4e1889c' target=_blank style='color:#2F92EE;'>#小青龙汤#</a>治疗常年性<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47188, encryptionId=616f4e1889c, topicName=小青龙汤), TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 01:46:03 CST 2023, time=2023-03-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1909503, encodeId=1edf1909503e8, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sat Dec 14 00:31:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903992, encodeId=fcd9190399265, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jan 17 02:31:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783551, encodeId=16ea1e83551ac, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Jun 06 03:31:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773288, encodeId=ac4b1e7328892, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Wed Jun 17 15:31:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323318, encodeId=0bb6132331834, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609918, encodeId=b9301609918a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 09 04:31:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370933, encodeId=5e0a3e09338c, content=所以,并没有客观证据显示治疗有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Thu Aug 08 07:00:30 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046886, encodeId=982b10468860d, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Aug 07 16:31:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370896, encodeId=88b93e0896e3, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Aug 07 14:02:31 CST 2019, time=2019-08-07, status=1, ipAttribution=)]
    2019-08-07 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Nat Commun:鼻甲基化组可以作为儿童哮喘和气道炎症的生物标记

鼻细胞表观基因组学可能能够作为气道疾病和环境响应的生物标记。最近,有研究人员从547名儿童(平均年龄12.9岁)中搜集了前鼻孔的鼻拭子并测量了DNA甲基化情况。研究人员对哮喘、过敏原敏感、过敏性鼻炎、呼出气一氧化碳(FeNO)和肺功能进行了鼻表观基因组关联分析(EWAS)。研究人员发现了哮喘(285-CPGS)、FeNO(8,372-CPGS;191-DMRs)、总IgE(3-CPGS;3-DMR

Biosci Rep:金银花提取物能够减轻卵清蛋白诱导的过敏性鼻炎

金银花具有抗病毒、抗氧化和抗炎症的特性。过敏性鼻炎(AR)是免疫球蛋白E(lgE)调控的炎症反应。最近,有研究人员调查了是否金银花提取物(HE)对AR具有治疗作用。研究发现,在AR模型中,HE不仅能够减少挠鼻和打喷嚏的次数,同时也能够减少AR诱导的鼻粘膜损伤。更多的是,HE能够降低血清lgE和组织胺的水平,抑制IL-4和IL-17水平,但能够增加鼻腔灌洗液中IL-2和IFN-γ水平。他们的结果同样

鼻炎太难受!盐水洗鼻用上就能缓解 但这2点没做好效果大打折扣

在现在的生活当中鼻炎出现的次数是非常多的,而且有非常多的人都患有鼻炎,鼻腔很容易成为人们的一个卫生死角,由于方法不当而不能全面彻底清除鼻腔中的有害物质,不少病毒、灰尘很可能在鼻腔中躲藏,从而引发感冒、充血、感染。据调查了解10个人里面大概有7个人都会患有鼻炎。盐水洗鼻是近几年来比较流行的治疗鼻炎新方法,效果不错、操作简单的盐水洗鼻成了很多鼻炎患者的首选,不过在使用这个方法的时候也有许多的误区。

Am J Otolaryngol:舌下尘螨滴液在单敏或者多敏过敏性鼻炎患者中的疗效和安全性评估

最近,有研究人员探索了舌下屋尘螨(HDM)滴液在单敏或者多敏过敏性鼻炎儿童中的疗效和安全性情况。研究是一个回顾性的群体研究,包括了65名单敏AR儿童和118名多敏AR儿童。这些耳聋在2015年1月到2016年6月进行HDM滴液舌下给药治疗。研究人员利用ELISA检测了IL-2、IL-4、IL-17α、转化生长因子-β1(TGF-β1)、特异性免疫球蛋白(lgE)和特异性lgG4的表达,并利用症状评

Int Forum Allergy Rhinol:HLA-II基因与过敏性鼻炎的特异性免疫治疗结果相关

治疗效果的关系,并评估了特异的多态性作为AIT受益AR患者生物标记的情况。研究包括了51名接受HDM AIT的中国AR患者。研究发现,等位基因DRB1*04:06; DRB1*14:05与鼻阻塞、鼻痒、眼痒和活动的改善具有正相关关系。相似的,DQB1*03:02:01; DQB1*05:03: 01与鼻阻塞、鼻痒、眼痒、行为问题和鼻症状评分具有正相关关系。 DRB1*03:01; DRB1*04:

盘点:鼻炎与治疗盘点

【1】BMC Cancer:减容调强放射治疗在鼻咽癌治疗中的优势分析 https://www.ncbi.nlm.nih.gov/pubmed/31176358鼻咽癌(NPC)治疗中,强度调节放射治疗(IMRT)中的临床靶标体积(CTV)定义尚未明确。最近,有研究人员评估了减容CTV IMRT治疗在鼻咽癌中的治疗情况。研究人员回顾了2002年到2013年IMRT治疗的293名非转移NPC患者数据